Joby Aviation closes $591 million stock offering with full underwriter option
Investing.com - H.C. Wainwright has reiterated a Buy rating and $4.00 price target on Vivani Medical, Inc. (NASDAQ:VANI), currently trading at $1.37, following the company’s announcement of clinical development plans for its semaglutide implant. The stock has shown remarkable momentum, gaining over 19% in the past week. According to InvestingPro data, the company has a market capitalization of approximately $80 million.
Vivani Medical revealed plans for NPM-139, its semaglutide implant designed for chronic weight management in patients who are obese or overweight with related comorbidities. The company expects to begin a Phase 1 trial in the first half of 2026, pending regulatory clearance. InvestingPro analysis indicates the company is currently burning through cash, with a weak overall financial health score - crucial factors to monitor as development progresses.
The planned Phase 1 trial will be randomized and controlled, evaluating safety, tolerability, and pharmacokinetic profile of NPM-139 against a control arm of low-dose weekly Wegovy injections. Results from this initial trial will help finalize the design for a subsequent Phase 2 study.
The Phase 2 trial will be a randomized, placebo-controlled, dose-ranging study conducted over 4-6 months to evaluate NPM-139’s effects on weight management in obese or overweight subjects. This second trial will commence shortly after Phase 1 completion, with the optimal dose advancing to Phase 3.
H.C. Wainwright believes NPM-139 has potential to demonstrate efficacy comparable to Wegovy while offering the advantage of convenient once or twice-yearly administration, supporting the firm’s maintained Buy rating and $4 price target. With a beta of 3.24, investors should note the stock’s high volatility. Unlock more insights and 8 additional ProTips with InvestingPro.
In other recent news, Vivani Medical, Inc. announced plans to initiate a Phase 1 clinical study for its semaglutide implant program NPM-139 in the first half of 2026, pending regulatory clearance. The company secured $10 million in equity financing to accelerate the development of this implant, with funding extending its financial runway into the second half of 2026. Additionally, Vivani Medical held its 2025 Annual Meeting of Stockholders, where all six nominees to the board of directors were elected to serve until the 2026 annual meeting. In a leadership update, Vivani appointed Anthony Baldor as Chief Financial Officer, succeeding Brigid A. Makes, who is retiring. Baldor brings over 20 years of financial management experience in the biotechnology sector, having previously served as CFO at Diakonos Oncology Corp. These developments highlight Vivani Medical’s strategic moves and ongoing efforts to advance its implant program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.